Antiplatelet drugs in cardiological practice: Established strategies and new developments

Vascular Health and Risk Management

Volumn 4, Issue 3, 2008, Pages 637-645

  Krötz, Florian ^a   Sohn, Hae Young ^a   Klauss, Volker ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Antiplatelet drug therapy; Atherothrombosis; Pathophysiology; Platelet activation

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ANTITHROMBOCYTIC AGENT; CANGRELOR; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; PLASMA PROTEIN; PRASUGREL; PURINERGIC P2Y12 RECEPTOR BLOCKING AGENT; PURINERGIC RECEPTOR BLOCKING AGENT; TERUTROBAN; THIENOPYRIDINE DERIVATIVE; TICAGRELOR; TICLOPIDINE; TIROFIBAN;

ACUTE CORONARY SYNDROME; ARTERY BLOOD FLOW; ARTERY THROMBOSIS; ATHEROSCLEROSIS; BLEEDING; CARDIOLOGY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; CORONARY STENT; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG EFFECT; DRUG FATALITY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; ENDOTHELIAL DYSFUNCTION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; OPTIMAL DRUG DOSE; PATHOPHYSIOLOGY; PRIMARY PREVENTION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; SINGLE DRUG DOSE; SOLID TUMOR; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; VASCULAR ENDOTHELIUM;

ATHEROSCLEROSIS; DRUG-ELUTING STENTS; HUMANS; PIPERAZINES; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PYRIDINES; RECEPTORS, PURINERGIC P2; RECEPTORS, THROMBOXANE; SIGNAL TRANSDUCTION; THIOPHENES; THROMBOSIS; TICLOPIDINE;

EID: 47849091670     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. 2005. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes, 54:2430-5.
2. Angiolillo DJ, Shoemaker SB, Desai B, et al. 2007. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation, 115:708-16.
3. Antithrombotic Trialists' Collaboration. 2002. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 324:(7329)71-86.
4. Awtry EH, Loscalzo J. 2000. Aspirin. Circulation, 101:1206-18.
5. Balsano F, Violi F, Cimminiello C. 1990. Ticlopidine in unstable angina. Circulation, 82:2282-3.
6. Belhassen L, Pelle G, Dubois-Rande JL, et al. 2003. Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin. J Am Coll Cardiol, 41:1198-204.
7. Bertrand ME, Rupprecht HJ, Urban P, et al. 2000. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation, 102:624-9.
8. Bhatt DL, Fox KA, Hacke W, et al. 2006. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med, 354:1706-17.
9. CAPRIE Steering Committee. 1996. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet, 348A9038)1329-39.
10. Cattaneo M. 2007. Platelet P2 receptors: old and new targets for antithrombotic drugs. Expert Rev Cardiovasc Ther, 5:45-55.
11. Chew DP, Bhatt DL, Sapp S, et al. 2001. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation, 103:201-6.
12. Cipollone F, Patrignani P, Greco A, et al. 1997. Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. Circulation, 96:1109-16.
13. Coccheri S. 2007. Approaches to prevention of cardiovascular complications and events in diabetes mellitus. Drugs, 67:997-1026.
14. Craven LL. 1953. Experiences with aspirin (Acetylsalicylic acid) in the nonspecific prophylaxis of coronary thrombosis. Miss Valley Med J, 75:38-44.
15. Daniel JL, Dangelmaier C, Jin J, et al. 1998. Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets. J Biol Chem, 273:2024-9.
16. De Schryver EL, Algra A, van Gijn J. 2007. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. Cochrane Database Syst Rev, 3:CD001820.
17. Diener HC, Bogousslavsky J, Brass LM, et al. 2004. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet, 364:(9431)331-7.
18. Dorsam RT, Kunapuli SP. 2004. Central role of the P2Y12 receptor in platelet activation. J Clin Invest, 113:340-5.
19. Dube C, Rostom A, Lewin G, et al. 2007. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med, 146:365-75.
20. Eisenstein EL, Anstrom KJ, Kong DF, et al. 2007. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA, 297:159-69.
21. Eshaghian S, Kaul S, Amin S, et al. 2007. Role of clopidogrel in managing atherothrombotic cardiovascular disease. Ann Intern Med, 146:434-41.
22. Evangelista V, Manarini S, Di Santo A, et al. 2006. De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin. Circ Res, 98:593-5.
23. Fuster V, Badimon L, Badimon JJ, et al. 1992. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med, 326:310-18.
24. Gawaz M, Langer H, May AE. 2005. Platelets in inflammation and atherogenesis. J Clin Invest, 115:3378-84.
25. Greenbaum AB, Grines CL, Bittl JA, et al. 2006. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Am Heart J, 151:689.
26. Halkes PH, van Gijn J, Kappelle LJ, et al. 2006. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet, 367:(9523)1665-73.
27. Huo Y, Schober A, Forlow SB, et al. 2003. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med, 9:61-7.
28. ISIS-2 Collaborative Group. 1988. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet, 2:(8607)349-60.
29. Jackson SP, Nesbitt WS, Kulkarni S. 2003. Signaling events underlying thrombus formation. J Thromb Haemost, 1:1602-12.
30. Jin J, Daniel JL, Kunapuli SP. 1998. Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J Biol Chem, 273:2030-4.
31. Kleinschnitz C, Pozgajova M, Pham M, et al. 2007. Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding. Circulation, 115:2323-30.
32. Kong DF, Califf RM, Miller DP, et al. 1998. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation, 99:2829-35.
33. Leger AJ, Covic L, Kuliopulos A. 2006. Protease-activated receptors in cardiovascular diseases. Circulation, 114:1070-7.
34. Loll PJ, Picot D, Garavito RM. 1995. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol, 2:637-43.
35. Manson JE, Stampfer MJ, Colditz GA, et al. 1991. A prospective study of aspirin use and primary prevention of cardiovascular disease in women. JAMA, 266:521-7.
36. Maree AO, Fitzgerald DJ. 2007. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation, 115:2196-207.
37. Mauri L, Hsieh WH, Massaro JM, et al. 2007. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med, 356:1020-9.
38. Neri Serneri GG, Coccheri S, Marubini E, et al. 2004. Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. Eur Heart J, 25:1845-52.
39. Nieswandt B, Watson SP. 2003. Platelet-collagen interaction: is GPVI the central receptor? Blood, 102:449-61.
40. Nyman I, Larsson H, Wallentin L. 1992. Prevention of serious cardiac events by low-dose aspirin in patients with silent myocardial ischaemia. The Research Group on Instability in Coronary Artery Disease in Southeast Sweden. Lancet, 340:(8818)497-501.
41. Patrignani P, Filabozzi P, Patrono C. 1982. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest, 69:1366-72.
42. Patrono C, Coller B, FitzGerald GA, et al. 2004. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 126:(3 Suppl)234S-264S.
43. Patrono C, Rocca B. 2007. Drug insight: aspirin resistance - fact or fashion? Nat Clin Pract Cardiovasc Med, 4:42-50.
44. Peto R, Gray R, Collins R, et al. 1988. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ (Clin Res Ed), 296:(6618)313-16.
45. Physician's Health Study Group. 1989. Physician's health study: aspirin and primary prevention of coronary heart disease. N Engl J Med, 321:1825-8.
46. Pinedo HM, Verheul HM, D'Amato RJ, et al. 1998. Involvement of platelets in tumour angiogenesis? Lancet, 352:(9142)1775-7.
47. Ridker PM, Cook NR, Lee IM, et al. 2005. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med, 352:1293-304.
48. Ruggeri ZM. 2003. Von Willebrand factor, platelets and endothelial cell interactions. J Thromb Haemost, 1:1335-42.
49. Schaper W. 2005. Dipyridamole, an underestimated vascular protective drug. Cardiovasc Drugs Ther, 19:357-63.
50. Shankar H, Kahner B, Kunapuli SP. 2006. G-protein dependent platelet signaling-perspectives for therapy. Curr Drug Targets, 7:1253-63.
51. Shattil SJ. 1995. Function and regulation of the beta 3 integrins in hemostasis and vascular biology. Thromb Haemost, 74:149-55.
52. Siess W. 1989. Molecular mechanisms of platelet activation. Physiol Rev, 69:58-178.
53. Stone GW, Ellis SG, Colombo A, et al. 2007. Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation. Circulation, 115:2842-7.
54. Thrombosis Prevention Trial Study Group. 1998. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet, 351:(9098)233-41.
55. Vilahur G, Casani L, Badimon L. 2007. A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis. Thromb Haemost, 98:662-9.
56. von Beckerath N, Kastrati A, Wieczorek A, et al. 2007. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J, 28:1814-19.
57. Wallentin LC. 1991. Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disease in Southeast Sweden. J Am Coll Cardiol, 18:1587-93.
58. Wang TH, Bhatt DL, Topol EJ. 2006. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J, 27:647-54.
59. Weiss HJ, Aledort LM, Kochwa S. 1968. The effect of salicylates on the hemostatic properties of platelets in man. J Clin Invest, 47:2169-80.
60. Wiviott SD, Antman EM, Winters KJ, et al. 2005. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation, 111:3366-73.
61. Wiviott SD, Braunwald E, McCabe CH, et al. 2007. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med, 357:2001-15.
62. Worth NF, Berry CL, Thomas AC, et al. 2005. S18886, a selective TP receptor antagonist, inhibits development of atherosclerosis in rabbits. Atherosclerosis, 183:65-73.